Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Background: Most people with type 2 diabetes are overweight, so initial treatment is aimed at reducing weight and increasing physical activity. Even modest weight loss can improve control of blood glucose. If drug treatment is necessary, the drug of first choice is metformin. However, some people ca...

Full description

Bibliographic Details
Main Authors: Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O’Hare, David McGrane, Tim Holt, Norman Waugh
Format: Article
Language:English
Published: NIHR Journals Library 2017-01-01
Series:Health Technology Assessment
Subjects:
canagliflozin
dapagliflozin
empagliflozin
monotherapy
type 2 diabetes
systematic review
economic evaluation
sglt2 inhibitors
Online Access:https://doi.org/10.3310/hta21020

Internet

https://doi.org/10.3310/hta21020

Similar Items